Show results for
Refine by
Locations
- Europe
- Albania
- Andorra
- Austria
- Belarus
- Belgium
- Bosnia & Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Faroe Islands
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Kosovo
- Latvia
- Liechtenstein
- Lithuania
- Luxembourg
- Macedonia
- Malta
- Moldova
- Monaco
- Montenegro
- Netherlands
- Northern Ireland
- Norway
- Poland
- Portugal
- Romania
- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
- Vatican City
Cancer Biomarker Equipment Supplied In Europe
15 equipment items found
by:Numares GROUP Corp based inRegensburg, GERMANY
Cancer is among the leading causes of death worldwide. Approximately 38 % of men and women will be diagnosed with cancer at some point during their lifetimes (based on 2013 – 2015 data1). Cancer can occur in any organ and in any cell type and the variability in clinical presentation makes early diagnosis difficult. Common ...
Manufactured by:Curasight based inKøbenhavn N, DENMARK
Curasight's uTRACE is a uPAR-PET imaging and diagnostics technology. It is used to find, visualise, and predict whether a cancer is aggressive and if so, how it should be treated. uTRACE has been tested on over 400 patients in several cancer forms and proven to be ...
Manufactured by:OraSure Technologies based inBethlehem, PENNSYLVANIA (USA)
Colli-Pee® 20 mL allows for standardized and volumetric urine collection of the first 20mL of urine flow. This has applications in infectious diseases and oncology. Collector tubes can be pre-filled with a preservative for different urinary analytes, improving transport and storage of urine at room ...
Manufactured by:Curasight based inKøbenhavn N, DENMARK
Curasight's uTREAT is new type of targeted radiation therapy, targeting and irradiating the cancer cells and almost not healthy tissue. By injecting a substance that seeks all cancer cells, including the metastases that are far away from the primary tumour, this offers a personalised and tailored therapy to each ...
Manufactured by:OraSure Technologies based inBethlehem, PENNSYLVANIA (USA)
Colli-Pee® Small Volumes tubes are compatible with high-throughput instruments and can streamline the pre-analytical process, shorten turnaround time, minimize errors as well as reduce costs. Collector tubes can be pre-filled with a preservative for different urinary analytes, improving transport and storage of urine at room ...
Manufactured by:OraSure Technologies based inBethlehem, PENNSYLVANIA (USA)
For detection and monitoring of cancers, as well as new biomarker development, a larger volume of urine can be required. Additionally, Colli-Pee® Large Volumes supports multi-omics research. Collector tubes can be pre-filled with a preservative for different urinary analytes, improving transport and storage of urine at room temperature. ...
Manufactured by:Inovarion based inParis, FRANCE
The latest advances in cancerology have made it possible to dissect the complexity of the signaling pathways leading to cancerous pathologies. New lines of thought have thus been drawn up in terms of therapies and tumor characterization. The mechanisms of oncogenesis, resistance to treatments and the identification of diagnostic biomarkers are major areas of ...
Manufactured by:SAGA Diagnostics AB based inLund, SWEDEN
ESR1 mutations are found in primary breast cancers prior to therapy initiation and are associated to worse relapse-free and overall survival. These results were reported today by a group of researchers from Lund University and Skåne University Hospital in a new studied published in JNCI Cancer ...
Manufactured by:Sysmex Partec GmbH based inGoerlitz, GERMANY
Plasma-SeqSensei (PSS) BC RUO Kit allows for the highly sensitive and specific detection of mutations in circulating tumour DNA (ctDNA) from the plasma of patients with breast cancer. The kit is based on the next-generation sequencing technology and covers key gene mutations such as AKT1, ERBB2, ESR1, KRAS, PIK3CA and TP53 to detect established and emerging predictive markers, ...
Manufactured by:Amadix based inValladolid, SPAIN
PancreaDix is an innovative, non-invasive signature in blood for: Confirming a Pancreatic cancer diagnosis. Detecting pre-malignant lesions that will evolve to cancer. Performing a differential diagnosis between Pancreatic cancer and other pathologies such as chronic pancreatitis or neuroendocrine tumors. ...
Manufactured by:CTIBiotech based inMeyzieu, FRANCE
Although much is known about the appearance, growth and spread of cancer in the human body, effective and rapid treatments for many cancer types are yet to be found. Chemo- and radio- therapies have made much progress in the last 20 years, but many such therapies are non-specific, leaving the patient to deal with severe side effects of the therapy and organ damage through cancer cell ...
Manufactured by:Datar Cancer Genetics based inGuildford, UNITED KINGDOM
CancertrackTM is a non-invasive blood based investigation that detects cancer derived biomarkers with ultra-high precision, specificity and reliability. CancertrackTM can be used to monitor the disease /recurrence or changes in the tumor characteristics, as often as necessary, without the cost, risk and consequences of radiation from scans, hospitalisation, ...
Manufactured by:OncoDNA S.A. based inGosselies, BELGIUM
Oncodeep® is a comprehensive biomarker test designed to guide treatment of advanced, metastatic solid tumors. When your patients are diagnosed with a rare cancer type or an aggressive cancer, when chemotherapy doesn't work or when cancer comes back, OncoDEEP® can provide you with clear clinical guidance. Starting from a ...
Manufactured by:OncoDNA S.A. based inGosselies, BELGIUM
OncoSELECT: Smart liquid biopsy panels with selected key genes per tumor type. The Liquid Biopsy Solution For Disease Monitoring Or Therapeutic Decision. OncoSELECT is a fast and minimally invasive analysis of circulating tumor DNA from a blood sample for lung (NSCLC), colorectal and breast (HR+ or HER2+) cancer patients. It is the perfect solution to identify therapeutic options for cancer ...
Manufactured by:MDxHealth based inIrvine, CALIFORNIA (USA)
SelectMDx Helps Physicians Determine if a Patient is at Higher or Lower Risk for Prostate Cancer and Which Men Can Safely Avoid Biopsy. A non-invasive urine test (“liquid biopsy”), SelectMDx measures the expression of two mRNA cancer-related biomarkers (HOXC6 and DLX1).1 The test provides binary results that, when combined with the ...